Followers | 840 |
Posts | 121789 |
Boards Moderated | 9 |
Alias Born | 09/05/2002 |

Friday, April 01, 2022 10:28:04 AM
https://finance.yahoo.com/news/merck-provides-fda-review-supplemental-104500754.html
Vaxneuvance is already FDA-approved for adults (#msg-164961310), but I don’t think Vaxneuvance will compete effectively with PFE’s Prevnar-20, which has broader coverage of pneumococcal serotypes and a simpler (one-shot) treatment course (#msg-166441188).
p.s. MRK pays PFE a royalty of 7.25% on worldwide Vaxneuvance sales during 2022-2026 and a 2.5% royalty during 2027-2035 (#msg-166075692).
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent MRK News
- Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill • Business Wire • 07/14/2025 01:31:00 PM
- FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health • Business Wire • 07/10/2025 08:45:00 PM
- U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection • Business Wire • 07/10/2025 10:45:00 AM
- Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio • IH Market News • 07/09/2025 01:06:42 PM
- Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade • Business Wire • 07/09/2025 10:30:00 AM
- Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025 • Business Wire • 07/08/2025 10:45:00 AM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (US) • 07/07/2025 02:13:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (US) • 07/07/2025 02:01:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (Canada) • 07/07/2025 02:01:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • InvestorsHub NewsWire • 07/07/2025 01:00:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (Canada) • 07/07/2025 12:30:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (US) • 07/07/2025 12:30:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (US) • 07/07/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 04:08:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 04:06:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 04:04:07 PM
- FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial • Business Wire • 07/02/2025 10:45:00 AM
- Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29 • Business Wire • 07/01/2025 10:45:00 AM
- Gilead Advances After Supreme Court Backs Preventive Care Coverage Under ACA • IH Market News • 06/30/2025 12:53:42 PM
- Form 11-K - Annual report of employee stock purchase, savings and similar plans • Edgar (US Regulatory) • 06/27/2025 06:16:51 PM
- Form 11-K - Annual report of employee stock purchase, savings and similar plans • Edgar (US Regulatory) • 06/27/2025 06:12:30 PM
- Form 11-K - Annual report of employee stock purchase, savings and similar plans • Edgar (US Regulatory) • 06/27/2025 06:08:51 PM
- ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season • Business Wire • 06/26/2025 05:39:00 PM
- Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention • Business Wire • 06/24/2025 10:45:00 AM
- Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH) • Business Wire • 06/23/2025 10:45:00 AM
A New Mining Model Built for Speed, Scale and Profit • AGI • Jul 17, 2025 9:00 AM
Rainmaker Announces Successful Deployment of Another Fully Containerized Seawater to Tap System in Turks and Caicos • RAKR • Jul 17, 2025 8:40 AM
Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies • FITY • Jul 17, 2025 8:30 AM
A New Mining Model Is Emerging - And Wall Street Is Paying Attention • B • Jul 15, 2025 9:00 AM
Sanwire Files Complaint Against Intercept Music and Trillium Partners • SNWR • Jul 15, 2025 9:00 AM
Cannabix Technologies Commences First Production of BreathLogix Alcohol Screening Devices • BLO • Jul 15, 2025 8:47 AM